Balance Sheet Components

9 Months Ended

Sep. 30, 2022

Balance Sheet Related Disclosures [Abstract]

Balance Sheet Components

8. Balance Sheet Components

Inventory

Inventory consisted of the following:

	September 30,
(in thousands)	2022
Raw materials	$	5,757
Work-in-progress		54,126
Finished goods		10,924
Total inventory	$	70,807

As of September 30, 2022, total inventory included net fair value adjustments resulting from the acquisition of La Jolla of approximately $64.1 million, which will be amortized and recognized as cost of products sold when sales occur in future periods. Amortization of fair value adjustments recorded as part of cost of products sold amounted to $2.7 million for the three and nine months ended September 30, 2022. There was no inventory as of December 31, 2021.

Other Accrued Liabilities

Other accrued liabilities consisted of the following:

	September 30,		December 31,
(in thousands)	2022		2021
Accrued contract manufacturing expenses	$	5,319	$	—
Accrued clinical expenses		1,062		—
Accrued research expenses		692		—
Accrued professional services		3,542		894
Current portion of lease liabilities		1,170		106
Accrued license fees and royalties		1,155		—
Other		2,180		9
Total other accrued liabilities	$	15,120	$	1,009

Other Long-term Liabilities

Other long-term liabilities consisted of the following:

	September 30,
(in thousands)	2022
Long-term portion of lease liabilities	$	2,703
Deferred royalty obligation		75,424
Contingent value rights liability		294
Total other long-term liabilities	$	78,421

There were no other long-term liabilities as of December 31, 2021.